Education
About Us
Working with TipRanks
Follow Us
Eyenovia (EYEN)
NASDAQ:EYEN
EYEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.85 - $124.80
Previous CloseN/A
Volume25.52M
Average Volume (3M)7.27M
Market Cap
$41.40M
Enterprise Value$38.58M
Total Cash (Recent Filing)$3.93M
Total Debt (Recent Filing)$11.15M
Price to Earnings (P/E)―
Beta2.94
Next Earnings
Aug 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding2,882,808
10 Day Avg. Volume9,142,872
30 Day Avg. Volume7,273,072
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-2.45
Price to Sales (P/S)0.00
P/FCF Ratio-1.27
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue205.59
Enterprise Value/Gross Profit-9.76
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$2.00Price Target Upside-86.07% Downside
Rating ConsensusHold
Number of Analyst Covering0
Eyenovia News
PremiumCompany Announcements
Eyenovia Rebrands to Hyperion DeFi, Focuses on CryptoBulls Say, Bears Say
Bulls Say
Merger And CollaborationThe proposed merger of topical ophthalmic platforms could present the next constructive chapter for Optejet and broader development.
Product DevelopmentCollaborations in dry eye disease development are seen as upside, with the user-filled Optejet potentially defining the most realistic shot for near-term progress.
Technology And InnovationEyenovia’s Optejet ophthalmic spray device is already FDA approved for Mydcombi, which is used for induced pupil dilation for eye exams and related surgery.
Bears Say
Clinical Trial FailuresThe Phase 3 CHAPERONE trial using the Optejet optimized spray dispenser for delivering MicroPine atropine for reduction of pediatric progressive myopia was discontinued.
Market RisksRisks to the investment thesis include failure of products and/or candidates to achieve peak commercial revenue estimates due to market size, penetration rates, and/or pricing.
Ownership Overview
11.34% Insiders
2.29% Mutual Funds
9.00% Other Institutional Investors
75.71% Public Companies and Individual Investors
EYEN FAQ
What was Eyenovia’s price range in the past 12 months?
Eyenovia lowest stock price was $0.85 and its highest was $124.80 in the past 12 months.
What is Eyenovia’s market cap?
Eyenovia’s market cap is $41.40M.
When is Eyenovia’s upcoming earnings report date?
Eyenovia’s upcoming earnings report date is Aug 06, 2025 which is in 18 days.
How were Eyenovia’s earnings last quarter?
Eyenovia released its earnings results on May 19, 2025. The company reported -$1.59 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.59.
Is Eyenovia overvalued?
According to Wall Street analysts Eyenovia’s price is currently Overvalued.
Does Eyenovia pay dividends?
Eyenovia does not currently pay dividends.
What is Eyenovia’s EPS estimate?
Eyenovia’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eyenovia have?
Eyenovia has 2,882,808 shares outstanding.
What happened to Eyenovia’s price movement after its last earnings report?
Eyenovia reported an EPS of -$1.59 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 47.788%.
Which hedge fund is a major shareholder of Eyenovia?
Currently, no hedge funds are holding shares in EYEN
Eyenovia Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (-86.07% Downside)
$2.00 (-86.07% Downside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.63%
12-Months-Change
Fundamentals
Return on Equity
-388.03%
Trailing 12-Months
Asset Growth
-77.14%
Trailing 12-Months
Company Description
Eyenovia
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.